Healthcare
Orchid Pharma Limited Unveils ‘soil to Vialfrom’ Initiative
Orchid Pharma Limited (ORCHPHARMA) reports strong Q2 FY27 results with a 148% surge in EBITDA, highlighting the success of its ‘Soil to VialFROM’ initiative.
Orchid Pharma Limited (ORCHPHARMA) has announced impressive financial results for Q2 FY27, marking a significant milestone with its ‘Soil to VialFROM’ initiative. The company’s standalone EBITDA surged by 148% compared to the same period last year, reflecting robust growth and operational efficiency. This remarkable performance underscores the successful integration of Orchid Pharma Limited and Dhanuka Laboratories Ltd., which was sanctioned under the NCLT scheme effective from July 10, 2026.
Financial Performance Highlights
The financial performance for Q2 FY27 showcases a 14% increase in revenue from operations, reaching Rs 341 crore. The gross margin improved to 15%, up from 7% in Q2 FY26. Notably, the EBITDA margin expanded to 12%, highlighting the company’s strong operational leverage. The profit after tax (PAT) for the quarter stood at Rs 37 crore, a substantial improvement from Rs 7 crore in Q2 FY26.
Strategic Growth Initiatives
The ‘Soil to VialFROM’ initiative, which spans from fermentation and biotransformation to finished dosage, is central to Orchid Pharma’s growth strategy. This comprehensive approach not only enhances the company’s capabilities in API manufacturing but also positions it as a leader in the global anti-infectives market. The initiative is expected to drive sustained long-term growth, leveraging Orchid Pharma’s 30 years of expertise in cephalosporin development.
As Orchid Pharma Limited continues to expand its footprint in regulated markets, the company remains committed to innovation and disciplined expansion, aiming to address the growing demand for novel antibiotics and advanced therapeutic solutions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Orchid Pharma Limited
Orchid Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Orchid holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 1.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -7.4% in three months on 22.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Orchid Pharma Limited.
GUJTHEM
Gujarat Themis Biosyn Limited Announces Strategic Acquisition of Microbiopharm Japan
Gujarat Themis Biosyn Limited (GUJTHEM) announces acquisition of MicroBiopharm Japan, enhancing its fermentation capabilities and expanding its CDMO services.
Gujarat Themis Biosyn Limited (GUJTHEM) announced the acquisition of MicroBiopharm Japan (MBJ), a strategic move aimed at enhancing its fermentation capabilities and expanding its contract development and manufacturing (CDMO) services. The acquisition, valued at JPY 9.5 Bn (INR 557 Cr), is expected to bolster GUJTHEM’s position in the global pharmaceutical market.
Enhanced Fermentation Capabilities
The acquisition of MBJ will provide GUJTHEM access to advanced fermentation, bio-conversion, and precision fermentation technologies. This will enable GUJTHEM to expand its product portfolio to include fermentation-based immunosuppressants, oncology APIs, and anti-infectives.
Diversified Product Portfolio
With the integration of MBJ’s technologies, GUJTHEM aims to transition from anti-TB and anti-infective APIs to specialty small molecules, biologics, and gene therapy products. This diversification will create multiple revenue streams, enhancing the company’s long-term growth prospects.
Global Expansion
The acquisition will also provide GUJTHEM with a global platform, leveraging MBJ’s established customer relationships and manufacturing base in Japan. This will facilitate market entry into Europe and the US, particularly in the plasmid market and CDMO services for immunosuppressants and precision fermentation.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.
Biotechnology
Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy
Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.
Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.
Key Financial Highlights
The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.
Segment Performance
The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.
However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.
As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.
BALAXI
Balaxi Pharmaceuticals Limited (NSE: Balaxi) Q2 & H1 FY27: Revenue Up 39%, PAT Surges 450%
Balaxi Pharmaceuticals Limited (NSE: BALAXI) reports strong Q2 & H1 FY27 results with revenue up 39% and PAT surging 450%.
Balaxi Pharmaceuticals Limited (NSE: BALAXI) continues to demonstrate robust growth in its branded, IPR-driven business model, particularly in frontier markets. In the first half of FY27, the company reported a 39% increase in revenue and a staggering 450% surge in PAT compared to the same period last year.
Strong Revenue Growth
The company’s total revenue for H1 FY27 stood at ₹16,023.35 crore, up from ₹12,672.58 crore in H1 FY26. This impressive growth is driven by Balaxi’s strategic focus on expanding its product portfolio and enhancing market presence in Africa and Latin America.
Profitability Boost
Profit After Tax (PAT) for H1 FY27 was ₹244.76 crore, a significant increase from ₹49.91 crore in H1 FY26. The PAT margin also improved from 0.39% to 1.53%. Earnings Per Share (EPS) surged from ₹0.09 to ₹0.44, reflecting the company’s strong financial performance.
Strategic Expansion
Balaxi Pharmaceuticals has added 37 new product registrations in H1 FY27, bringing the total to over 1,000 registered products. The company’s manufacturing facility in Jadcherla, Telangana, is ramping up commercial production, which is expected to capture margins previously paid to contract manufacturers and open new market opportunities.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of BALAXI PHARMACEUTICALS LIMITED
BALAXI PHARMACEUTICALS LIMITED belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
BALAXI moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue contracts at -7.1% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at -7.1% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of BALAXI PHARMACEUTICALS LIMITED.
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2 FY27: Disbursements Rise 62% Qoq and PAT Grows 28%
-
Capital Markets3 days agoMaster Trust Limited (mastertr): Mastercapitalservices Raises ₹75 Cr Through Ncds
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Investor Presentation Q2 & H1 FY27 Highlights
-
Healthcare3 days agoZydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
-
MAXESTATES2 days agoMax Estates Limited (maxestates) Reimagines Luxury Living Through ‘the Bungalows’
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2fy27 Investor Presentation: Strong Growth and Expansion
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Q2 FY27: Revenue Growth of 34%, Retail Expansion Adds 14 Showrooms
-
Communication Equipment3 days agoTamilnadu Telecommunication Limited (tntele) Reports Q2 FY27: Net Loss Deepens